狄诺塞麦的用法用量

It is the first approved monoclonal antibody specifically targeting RANK ligand. RANK ligand is a transmembrane or soluble protein that is necessary for osteoclasts to maintain their structure, function, and survival. Human RANKL mRNA is mainly found in bones, bone marrow and lymphoid tissues. Its main function in bones is to stimulate the differentiation and activity of osteoclasts and inhibit the apoptosis of osteoclasts. Osteoclasts are responsible for bone resorption, and osteoclast precursors must have low levels of macrophage colony-stimulating factor and RANKL during their differentiation into mature osteoclasts. Denosumab has a high affinity with RANKL, preventing RANK ligand from activating RANK on the surface of osteoclasts, inhibiting osteoclast activation and development, reducing bone resorption, increasing bone density and bone strength of both cortical bone and trabecular bone, promoting bone reconstruction, and reducing the incidence of vertebral, non-vertebral and hip fractures in postmenopausal osteoporotic women.

On May 28, 2010, the European Commission approved denosumab for the treatment of bone loss associated with hormone suppression in postmenopausal women with osteoporosis and prostate cancer. It can also be used in patients who are currently ineffective or intolerant to other treatments to reduce the risk of fractures. Denosumab was approved for the first time in 27 EU member states, as well as Norway, Iceland, and Liechtenstein. In June of the same year, denosumab was approved by the FDA.

1. Xgeva can only be injected subcutaneously, not intravenously, intramuscularly or intradermally.

2. Bone metastasis of solid tumors: 120mg once every 4 weeks, injected subcutaneously in the upper arm, thigh or abdomen.

3. Giant cell tumor of bone: 120 mg once every 4 weeks, subcutaneous injection, and then 120 mg on d8 and d15 in the first month of treatment.

4. Administer calcium and vitamin D appropriately to prevent hypocalcemia.

5. Malignant hypercalcemia: 120 mg once every 4 weeks, subcutaneous injection, and then 120 mg on d8 and d15 in the first month of treatment. The medication is injected under the skin in the upper arm, thigh, or abdomen.

6. Pregnancy: According to animal data, it may cause fetal damage. Pregnancy monitoring programs available

7. Breastfeeding mothers: Breast development and lactation may be impaired. Discontinue medication or breastfeeding

8. Pediatric patients: Solace and effectiveness have not been determined

9. Renal impairment: Patients with creatinine clearance less than 30 mL/min or receiving dialysis are at risk for hypocalcemia. Appropriate supplements of calcium and vitamin D.

Each drug will produce different therapeutic effects and adverse reactions, so patients must carefully ask their doctor about the basic knowledge about the drug before using it, so as not to affect their health due to minor problems.